Trial Profile
Dose-escalation Study to Assess the Safety and Tolerability of Sub-cutaneous Injections of a Peptide-loaded Plasmacytoid Dendritic Cell Line (GeniusVac-Mel4) in Patients With Melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs GeniusVac Mel4 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; First in man
- 01 Apr 2020 According to a PDC*line Pharma media release, results from this trial were published in OncoImmunology.
- 01 Apr 2020 Results presented in the PDC*line Pharma Media Release.
- 10 Nov 2017 Status changed from recruiting to completed.